Investors Annual Results - Cover tab

Annual results 2023 - Jan 31, 2024

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.6 MB)

Webcast and presentation

Watch the webcast

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)

Download 2023 epidemiology data (PDF 1.1 MB)

 

Shanelle Gabriel spending time with her father in New York

Novartis in Society Integrated Report 2023

This report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.
 

Download the Integrated Report (PDF 8.4 MB)

View the online summary
K. Balamani with her daughter at home in Sollakpally, near Hyderabad, India

Annual Report 2023 and US Securities & Exchange Commission Form 20-F 2023

These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.
 

Annual Report 2023 (PDF 3.7 MB) | Form 20-F 2023 (PDF 3.5 MB)

Order the publications

Annual results 2023 - Jan 31, 2024

Key figures1

Continuing operations2

 FY 2023
(USD m)		FY 2022
(USD m)		% change
(USD/cc)
Net sales45,44042,2068 (cc: 10)
Operating income9,7697,94623 (cc: 39)
Net income8,5726,04942 (cc: 62)
EPS (USD)4.132.7749 (cc: 70)
Free cash flow13,16012,1239

Core		   
Operating income16,37214,79411 (cc: 18)
Net income13,44611,94613 (cc: 19)
EPS (USD)6.475.4818 (cc: 25)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.6 MB)

Watch the webcast

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)

Download 2023 epidemiology data (PDF 1.1 MB)

Annual results 2022 - Feb 01, 2023

Key figures1FY 2022
(USD m)		FY 2021
(USD m)		% change
(USD/cc)
Net sales50,54551,626-2 (cc: 4)
Operating income9,19711,689-21 (cc: -13)
Net income6,95524,018-71 (cc: -67)
EPS (USD)3.1910.71-70 (cc: -66)
Free cash flow11,94513,282-10

Core		   
Operating income16,66516,5880 (cc: 8)
Net income13,35214,094-5 (cc: 3)
EPS (USD)6.126.29-3 (cc: 6)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)

Read the presentation transcript

Novartis ESG Update Q4 2022 (PDF 0.9 MB)

Annual results 2021 - Feb 02, 2022

Key figures1FY 2021
(USD m)		FY 2020
(USD m)		% change
(USD/cc)
Net sales51,62648,6596 (cc: 4)
Operating income11,68910,15215 (cc: 13)
Net income24,0188,071198 (cc: 195)
EPS (USD)10.713.55202 (cc: 200)
Free cash flow13,28211,69114

Core		   
Operating income16,58815,4168 (cc: 6)
Net income14,09413,1587 (cc: 5)
EPS (USD)6.295.789 (cc: 7)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the podcast (MP3 43 MB)

Read the presentation transcript

Download the presentation (PDF 4.9 MB)

Novartis ESG Update - February 03, 2022 (PDF 1.7 MB)

Annual results 2020 - Jan 26, 2021

Key figures2

Continuing operations1

 FY 2020
(USD m)		FY 2019
(USD m)		% change
(USD/cc)
Net sales48,65947,4453 (cc: 3)
Operating income10,1529,08612 (cc: 19)
Net income8,0717,14713 (cc: 20)
EPS (USD)3.553.1214 (cc: 21)
Free cash flow11,69112,937-10

Core		   
Operating income15,41614,1129 (cc: 13)
Net income13,15812,1049 (cc: 12)
EPS (USD)5.785.289 (cc: 13)
  1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Condensed financial report (PDF 0.6 MB)

Annual results 2019 - Jan 29, 2020

Key figures2

Continuing operations1

 FY 2019
(USD m)		FY 2018
(USD m)		% change
(USD/cc)
Net sales47,44544,7516 (cc: 9)
Operating income9,0868,4038 (cc: 14)
Net income7,14712,800-44 (cc: -41)
EPS (USD)3.125.52-43 (cc: -40)
Free cash flow12,93711,25615

Core		   
Operating income14,11212,55712 (cc: 17)
Net income12,10410,92011 (cc: 15)
EPS (USD)5.284.7112 (cc: 17)
  1. Refers to continuing operations as defined on page 45 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.1 MB) | Deutsch (PDF 0.1 MB) | Français (PDF 0.1 MB)

Condensed financial report (PDF 0.6 MB)

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.